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ABSTRACT 33 
PURPOSE: -alanine (BA) supplementation improves human exercise performance. One 34 
possible explanation for this is an enhancement of muscle contractile properties, occurring 35 
via elevated intramuscular carnosine resulting in improved calcium sensitivity and handling. 36 
This study investigated the effect of BA supplementation on in vivo contractile properties and 37 
voluntary neuromuscular performance. METHODS: Twenty-three men completed two 38 
experimental sessions, pre- and post-28 days supplementation with 6.4 g·d
-1
 of BA (n = 12) 39 
or placebo (PLA; n = 11). During each session, force was recorded during a series of knee 40 
extensor contractions: resting and potentiated twitches and octet (8 pulses, 300 Hz) 41 
contractions elicited via femoral nerve stimulation; tetanic contractions (1 s, 1 – 100 Hz) via 42 
superficial muscle stimulation; and maximum and explosive voluntary contractions. 43 
RESULTS: BA supplementation had no effect on the force-frequency relationship, or the 44 
force responses (force at 25 ms and 50 ms from onset, peak force) of resting or potentiated 45 
twitches, and octet contractions (P > 0.05). Resting and potentiated twitch electromechanical 46 
delay and time-to-peak tension were unaffected by BA supplementation (P > 0.05), although 47 
half-relaxation time declined by 7-12% (P < 0.05). Maximum and explosive voluntary forces 48 
were unchanged after BA supplementation. CONCLUSION: BA supplementation had no 49 
effect on evoked force responses, implying that altered calcium sensitivity and/or release are 50 
not the mechanisms by which BA supplementation influences exercise performance. The 51 
reduced half-relaxation time with BA supplementation might, however, be explained by 52 
enhanced reuptake of calcium, which has implications for the efficiency of muscle 53 
contraction following BA supplementation. 54 
Key words: beta-alanine; muscle contractile properties; electrical stimulation; force-55 
frequency relationship 56 
  57 
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INTRODUCTION 58 
Carnosine (β-alanyl-L-histidine) is a cytoplasmic dipeptide synthesised from -alanine (BA) 59 
and histidine, and is found in high concentrations within mammalian skeletal muscle. 60 
Carnosine is formed, primarily in skeletal and brain tissue, by bonding histidine and BA in a 61 
reaction catalysed by carnosine synthase (23; 40). The availability of BA in the human diet is 62 
the rate-limiting factor for carnosine synthesis in human skeletal muscle [for a brief review 63 
see (20)]. Long-term (4-10 weeks) dietary supplementation with BA significantly increases 64 
human skeletal muscle carnosine content (19; 21; 24). Interest in elevating carnosine levels 65 
through BA supplementation has dramatically increased since it was first shown that doing so 66 
increased high-intensity cycling capacity (21). Since then, it has been well established that 67 
BA supplementation can improve high-intensity exercise performance (e.g. 2000 m rowing 68 
performance and 100-200 m swimming performance) and capacity during exercise of ~1-6 69 
minutes [see reviews: (22; 34)]. However, the physiological mechanisms for these ergogenic 70 
effects remain poorly understood. 71 
 72 
Carnosine is suggested to have several physiological roles in muscle, which are pertinent to 73 
muscle function and performance. For example, its molecular structure makes it well suited 74 
to act as a pH buffer (36).  The pKa of its imidazole ring is 6.83, placing it right in the middle 75 
of the pH transit range of exercising muscle.  This means that an increase in carnosine 76 
content within the skeletal muscles also results in an expansion of the imidazole ring content, 77 
concomitantly increasing the muscle buffering capacity. As a result, performance 78 
improvements in high-intensity exercise (particularly when hydrogen cation accumulation is 79 
likely to limit performance) have largely been ascribed to increases in intracellular buffering 80 
[see review: (34; 35)].  81 
 82 
Alternative mechanisms for the enhancement of exercise performance following BA 83 
supplementation have been proposed. For example, previous work in rat skeletal muscle 84 
suggested a role for carnosine in increasing the sensitivity of the contractile apparatus to 85 
calcium ions (Ca
2+
) (10). More recent work in skinned human m. vastus lateralis fibre 86 
preparations showed a similar increase in Ca
2+
 sensitivity (11). Although only slight changes 87 
were shown in the maximum Ca
2+
 activated force (≤3%), a significant leftward shift in the 88 
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force-calcium concentration relationship was shown, indicating that force for a given 89 
submaximal Ca
2+
 concentration was increased in the presence of higher carnosine levels in 90 
both fibre types. Elevated carnosine levels also increased Ca
2+
 release from the sarcoplasmic 91 
reticulum of type I fibres, whereby carnosine appeared to enhance the Ca
2+
 sensitivity of 92 
ryanodine receptors and potentiated Ca
2+
 induced Ca
2+
 release (11). Thus, it was suggested 93 
that elevated carnosine after BA supplementation could alleviate the decline in contractile 94 
performance during fatiguing contractions by countering factors that might cause reduced 95 
calcium sensitivity and release (11).   96 
 97 
A recent study provided the first evidence that dietary BA supplementation may influence the 98 
muscle contractile properties of mice (13), potentially via elevated intramuscular carnosine 99 
and its effect on calcium sensitivity and handling (11). BA supplementation was associated 100 
with a leftward shift in the electrically-evoked force-frequency relationship of excised 101 
muscle, which is analogous to the force-calcium concentration relationship (5; 27), eliciting a 102 
10-30% increase in the force produced at low stimulation frequencies (13). However, the 103 
possibility that dietary BA supplementation might change in vivo human muscle contractile 104 
properties, and thus voluntary muscle performance, has not been investigated.  There is a 105 
need to examine this possibility given that we would expect a wider range of performance 106 
effects of carnosine than have currently been shown if improved calcium handling were the 107 
major physiological role of carnosine in human skeletal muscle (34).  108 
 109 
As such, we examined the effects of 28 d BA supplementation on the intrinsic contractile 110 
properties of human skeletal muscle in vivo, as well as on voluntary muscle function. Intrinsic 111 
contractile properties were assessed via the force-frequency relationship in response to 112 
muscle stimulation, and the evoked twitch and octet [8 pulses at 300 Hz, which drives the 113 
muscle at its maximum capacity for rapid or “explosive” force production; (8)] responses to 114 
supramaximal nerve stimulation. We hypothesised that BA supplementation would enhance 115 
intrinsic contractile properties; producing a left-ward shift in the force-frequency relationship; 116 
increasing the peak and explosive force responses to twitch and octet stimulation and 117 
increasing explosive voluntary force production. In addition, we hypothesised that the altered 118 
contractile properties would lead to changes in motor control, reflected as a shift in the force-119 
electromyography (EMG) relationship towards lower EMG levels for a given level of force.  120 
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METHODS 121 
Participants 122 
Twenty-six participants were recruited to the study and were stratified and allocated to the 123 
two supplement groups [placebo (PLA) or β-alanine (BA)] on the basis of maximum knee 124 
extensor strength (maximum voluntary force, MVF; see below) values recorded during the 125 
familiarisation session, such that the two groups were matched for knee extensor strength. 126 
However, three participants withdrew from the study (two from PLA and one from BA), one 127 
during familiarisation due to a lack of tolerance of electrical stimulation and two following 128 
baseline testing with no reason provided. As such, twenty-three participants completed all 129 
aspects of the study (PLA group: n = 11; age, 25.6 ± 5.6 y; body mass, 79.1 ± 13.0 kg; height, 130 
1.80 ± 0.07 m; BA group: n = 12; age, 26.1 ± 7.4 y; body mass, 90.1 ± 32.1 kg; height, 1.79 ± 131 
0.06 m). All participants provided written informed consent, and completed this study, which 132 
was approved by the Institutional Human Ethical Review Committee. None of the 133 
participants had taken any nutritional supplements in the previous 6 months. Participants had 134 
no injuries to the lower limbs, were not involved in any systematic physical training, and 135 
were categorised as having moderate habitual levels of physical activity using the 136 
International Physical Activity Questionnaire Short Format [http://www.ipaq.ki.se/ipaq.htm; 137 
(7)]. Throughout the study participants were requested to maintain similar levels of physical 138 
activity and dietary intake; this was verbally confirmed at the start of each session. None of 139 
the subjects were vegetarian or vegan, and therefore they would likely have encountered 140 
small amounts of BA in their diet (1).  141 
 142 
Study design 143 
This was a double-blind placebo controlled experiment. Participants completed three 144 
experimental sessions over a five week period: a familiarisation session, which preceded a 145 
baseline session by at least 7 days, and a follow-up session after 28 days of supplementation 146 
with either BA or PLA. Participants were instructed to abstain from alcohol and 147 
strenuous/unaccustomed exercise for 36 hours prior to measurement sessions, with caffeine 148 
prohibited on the day of measurement sessions. Compliance with these requests was 149 
confirmed verbally with each participant prior to them commencing each session. 150 
Measurement sessions were completed at a consistent time of day, with recordings of force 151 
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and surface EMG during a series of voluntary and involuntary (electrically evoked) isometric 152 
contractions of the knee extensors of the dominant leg. The familiarisation session involved 153 
all the voluntary and evoked contractions, except the evoked octet contractions. The baseline 154 
and follow-up sessions involved an identical protocol performed according to a strict 155 
schedule. All raw data, exclusions and statistical analyses were completed blind to 156 
supplement group. 157 
 158 
Supplementation 159 
Participants received 6.4 g·d
-1
 of either BA (sustained-release Carnosyn
TM
) or a matched 160 
placebo (PLA, maltodextrin) for 28 days (2 × 800mg tablets, ingested 4 times per day). The 161 
sustained-release formulation used in this study has been shown to reduce or remove the 162 
paraesthesia often experienced by participants following doses of free BA powder (9). We 163 
would expect the increase in muscle carnosine content to be close to 15 mmol.kg
-1
 dry muscle  164 
(an increase of circa 65% in a participant eating a mixed diet), given that Harris et al. (2006) 165 
reported this level of increase following a similar but slightly lower total dose of BA. None of 166 
the participants reported any feelings of paraesthesia during the study. Throughout 167 
supplementation participants completed a log to verify supplement compliance, with similar 168 
compliance reported at 91 ± 7% in the BA group and 88 ± 10% in the PLA group 169 
(independent sample t-test, P = 0.60). 170 
 171 
Supplements were provided to each participant in identical white tubs by an individual not 172 
directly involved in testing or data analysis, in order to maintain the double-blind.  BA tablets 173 
were tested by the manufacturer prior to release for the study and conformed to the label 174 
claim for BA content. In addition, BA and PLA supplements were independently tested by 175 
HFL Sports Science, UK, prior to use to ensure no contamination with steroids or stimulants 176 
according to ISO 17025 accredited tests. 177 
 178 
Experimental set-up 179 
Knee extension force 180 
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Participants were seated in a rigid, custom-built dynamometer with hip and knee joint angles 181 
of approximately 95° and 100° (180° = full extension), as adapted from previous studies (17; 182 
18).  Adjustable strapping across the pelvis and shoulders prevented extraneous movement 183 
during muscle activation.  An ankle cuff was attached to the dominant leg of the participant 184 
~2 cm proximal to the medial malleolus and was in series with a linear strain gauge (615, 185 
Tedea-Huntleigh, Herzliya, Israel) oriented perpendicular to the tibia. Dynamometer 186 
configuration was established during the familiarisation session and replicated thereafter.  187 
The force signal was amplified (×1000) in the frequency range of 0 – 500 Hz, and sampled at 188 
2000 Hz using an external A/D converter (1401; CED, Cambridge, UK), interfaced with a 189 
personal computer (PC) using Spike 2 software (CED, Cambridge, UK).  Force data were 190 
low-pass filtered in both directions at 450 Hz using a fourth-order zero-lag Butterworth filter 191 
prior to analysis. Baseline resting force was subtracted from all force recordings to correct for 192 
the effects of gravity.  193 
 194 
Electromyography (EMG) 195 
EMG signals were recorded from the superficial quadriceps: m. rectus femoris (RF), m. 196 
vastus medialis (VM) and m. vastus lateralis (VL).  After preparation of the skin by shaving, 197 
light abrasion and cleaning with alcohol, bipolar surface electrodes (2.5 cm inter-electrode 198 
distance; silver/silver chloride, 95 mm
2
 area, Ambu Blue Sensor, Ambu, Ballerup, Denmark) 199 
were attached over each muscle at standardised percentages of thigh length, as measured 200 
from the knee joint space to the greater trochanter: RF, 55%; VM, 25% and VL, 45%. These 201 
sites were selected to avoid the innervation zones of each of the assessed muscles (32).  A 202 
reference electrode was placed on the patella of the same limb. EMG signals were pre-203 
amplified by active EMG leads (input impedance 100 MΩ, CMMR > 100 dB, base gain 500, 204 
1st order high pass filter set to 10 Hz; Noraxon, Scottsdale, U.S.A) connected in series to a 205 
custom-built junction box and subsequently to the same A/D converter and PC software that 206 
enabled synchronisation with the force data.  The signals were sampled at 2000 Hz.  EMG 207 
data were band-pass filtered in both directions between 20 and 450 Hz using a fourth-order 208 
zero-lag Butterworth filter prior to analysis.  209 
 210 
Electrical stimulation 211 
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A constant current variable voltage stimulator (DS7AH, Digitimer Ltd, Welwyn Garden City, 212 
UK) was used to assess knee extensor contractile properties whilst the participant was 213 
voluntarily passive. Square-wave pulses (0.2 ms duration) were delivered via: (i) 214 
supramaximal femoral nerve stimulation to evoke maximal resting twitch, potentiated twitch 215 
and octet contractions; (ii) percutaneous sub-maximal muscle stimulation to evoke 216 
contractions at a range of frequencies (1 to 100 Hz) to assess the force-frequency 217 
relationship. Femoral nerve stimulation involved a cathode stimulation probe (1 cm diameter, 218 
Electro-Medical Supplies Ltd, Wantage, UK) firmly pressed into the skin over the femoral 219 
nerve in the femoral triangle, and an anode (7×10 cm carbon rubber electrode; Electro-220 
Medical Supplies Ltd, Wantage, UK) coated with electrode gel and taped to the skin over the 221 
greater trochanter. The precise location of the cathode was determined as the position that 222 
evoked the greatest twitch response for a particular submaximal electrical current (typically 223 
30–50 mA). For percutaneous stimulation, the surfaces of two carbon rubber electrodes (14 × 224 
10 cm; Electro-Medical Supplies Ltd, Wantage, UK) were coated with electrode gel and 225 
secured over the proximal and distal surface of quadriceps at standardised percentages of 226 
thigh length, as measured from the patella to the anterior superior iliac spine (ASIS): 227 
proximal electrode placed 20% distal to the ASIS; distal electrode placed 10% proximal to 228 
the patella. 229 
 230 
Protocol and measurements 231 
Measurements were completed in the following order, according to a consistent time 232 
schedule including ≥ 3 minutes rest between successive measurements.  233 
Force and EMG onsets for all evoked and voluntary contractions were identified manually 234 
using visual identification by the same investigator, in accordance with a previously 235 
published method (16; 37).  This approach is considered more valid than the use of automated 236 
methods of identification (38).  237 
 238 
Resting twitches 239 
Resting twitches were evoked following ≥15 min passive sitting, in order to remove any 240 
lingering potentiation, which incorporated the time for securing the participant in the 241 
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dynamometer, and preparing them for EMG and electrical stimulation.  Single electrical 242 
impulses were delivered with stepwise increments in the current, separated by 10 s to allow 243 
for neuromuscular recovery, until a plateau in the amplitude of twitch force and compound 244 
muscle action potentials (M-waves) were reached. The stimulus intensity was then increased 245 
by 25% above the value required to elicit a plateau to ensure supramaximal stimulation, and 246 
three discrete supramaximal stimuli separated by 10 s were then delivered to elicit maximal 247 
twitch responses and M-waves.  248 
 249 
The time difference between M-wave onset (first electrode site to be activated) and twitch 250 
force onset was defined as the electromechanical delay (EMD). Twitch force was measured at 251 
25 and 50 ms from onset, as markers of the explosive force production during the rising 252 
slope, and at the peak of the force response. The time-to-peak tension (TPT) and half-253 
relaxation time (HRT) were also recorded. All measurements were averaged across the three 254 
maximal twitch contractions. The M-wave response for the three quadriceps electrodes was 255 
measured for M-wave area, from EMG onset to the point where the signal returned to 256 
baseline, and averaged across the three sites. The mean M-wave area of the three 257 
supramaximal stimuli was defined as the maximal M-wave area (Mmax) and was used for 258 
normalisation of voluntary quadriceps EMG (6). 259 
 260 
Maximum voluntary contractions and potentiated twitches 261 
A brief warm-up of 3 sub-maximal knee extension contractions at 50%, 75% and 90% of the 262 
participants’ perceived maximal force were performed; contractions lasted ~3 s each and 263 
were separated by ~20 s. Participants then completed 4 maximum voluntary contractions 264 
(MVCs) of the knee extensors ≥60 s apart, during which they were instructed to contract “as 265 
hard as possible” for 3-4 s. During and after each contraction they received strong verbal 266 
encouragement reiterating the instructions, together with online feedback of the force signal 267 
and a marker of their maximum force during that session displayed onscreen. Supramaximal 268 
stimulation of the femoral nerve, using the same configuration and stimulus intensity as for 269 
resting twitches, was used to elicit a maximal potentiated twitch ~1 s after each of the MVCs. 270 
The greatest instantaneous force during either the knee extensor MVCs or explosive 271 
voluntary contractions (see below) of that trial was defined as MVF. The root mean square 272 
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(RMS) of the EMG signal for each muscle (RF, VM, VL) was calculated over a 500 ms 273 
epoch surrounding MVF (250 ms either side) and normalised to the corresponding Mmax (6), 274 
before averaging across all 3 sites to calculate a mean quadriceps value. The EMD, force at 275 
25 and 50 ms from onset, peak twitch force, TPT and HRT were averaged across the four 276 
maximal potentiated twitch contractions. 277 
 278 
Explosive voluntary contractions 279 
The protocol followed previously published procedures (6; 16). Participants completed ≥10 280 
isometric explosive voluntary knee extensions, each separated by ~20 s. Starting from a 281 
completely relaxed state, they were instructed to respond to an auditory signal by extending 282 
their knee “as fast and hard as possible” for ~1 s, with an emphasis on “fast”. An on-screen 283 
cursor was used to provide online feedback on their explosive performance, displaying the 284 
maximum rate of force development (2 ms time constant) of their best attempt. Strong verbal 285 
encouragement was provided to participants to exceed this target during each subsequent 286 
contraction. A second visual marker on the screen depicted 80% of the peak force recorded 287 
during MVCs, which participants were expected to achieve or exceed during each explosive 288 
contraction. Resting force was also displayed on a sensitive scale during all explosive 289 
contractions to aid the detection of pretension or countermovement. The explosive 290 
contractions were performed until 10 contractions, with no prior countermovement or pre-291 
tension, been had been recorded. 292 
 293 
The three contractions with the greatest maximum rate of force development, meeting the 294 
following criteria, were used for analysis: (i) no prior countermovement or pre-tension, and 295 
(ii) peak force ≥80% MVF. Analyses involved measurement of the force–time and EMG–296 
time traces in short periods after their onsets. Explosive force was measured at 25 ms 297 
intervals up to 150 ms after force onset. The RMS of the EMG signal from each muscle was 298 
measured over three consecutive 50 ms time periods from EMG onset of the first agonist 299 
muscle to be activated (i.e., 0-50, 50-100 and 100-150 ms). Thereafter, RMS EMG at each 300 
EMG site was normalized to Mmax and averaged to provide a mean quadriceps value. All 301 
measurements were averaged across the three selected contractions. 302 
 303 
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Force-EMG relationship (via voluntary incremental knee extension contractions) 304 
A series of submaximal knee extension contractions were performed at 15% increments of 305 
MVF, in ascending order, up to 90%. Horizontal cursors on the screen in front of participants 306 
depicted the target levels of force. Participants were instructed to reach the target quickly and 307 
maintain the level of force as accurately as possible for ~3 s. Contractions were separated by 308 
~20 s. The RMS of the EMG and average force over a stable 500 ms part of the force trace 309 
(minimal standard deviation of the force trace for that contraction) were analysed at each of 310 
the contraction intensities. The EMG RMS values were normalised to Mmax and plotted 311 
against the respective force values. Linear regression was used to evaluate the slope and 312 
intercept of the force-EMG relationship incorporating all data between 15 – 90% MVF.  313 
 314 
Octet contractions  315 
Octet contractions [8 impulses at 300 Hz; (8)] were evoked via supramaximal stimulation of 316 
the femoral nerve.  First, a brief series of single stimuli were administered, and twitch force 317 
and M-wave amplitudes were monitored to confirm that the stimuli were supramaximal. The 318 
current was increased if necessary to ensure supramaximal stimulation. Then 3 discrete pulse 319 
trains (≥15 s apart) were delivered with a supramaximal current (+25%) to evoke maximal 320 
octet contractions. The current increased by ~5% after each pulse train in order to confirm a 321 
plateau in both the peak force and maximum rate of force development. On some occasions, 322 
where the first pulse train elicited a submaximal response, a 4
th
 pulse train was delivered to 323 
ensure 3 maximal responses. The octet force response was measured at 25 and 50 ms from 324 
force onset, as well as at the peak. All measurements were averaged across the 3 analysed 325 
contractions.  326 
 327 
Force-frequency relationship  328 
Surface EMG electrodes were removed and carbon rubber electrodes attached over the 329 
quadriceps, taking ~5 minutes. The force-frequency relationship was then evaluated during 330 
tetanic contractions elicited via submaximal percutaneous electrical stimulation (3; 15).  331 
Initially, 100 Hz contractions were evoked at increasing current intensities, ≥30 s apart, to 332 
determine the current that elicited 50% of baseline MVF. This current (typically 110 – 200 333 
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mA) was then used for the following force-frequency measurements. The final calibration 334 
contraction at 100 Hz and the subsequent measured contractions were separated by ≥60 s. 335 
The force-frequency relationship contractions consisted of two twitch contractions (1 Hz), 336 
followed by single contractions of 1 s duration at each of 9 different frequencies (5, 10, 15, 337 
20, 30, 40, 50, 80, 100 Hz) performed in ascending order with ~30 s between contractions. 338 
Peak force was defined as the greatest instantaneous force. Thereafter, the force values at 339 
each stimulation frequency were normalized to 100 Hz force. The force-frequency 340 
relationship was fitted with a Hill curve and evaluated for frequency at 50% of the maximum 341 
force response (11). 342 
 343 
Statistical Analysis 344 
Dependent variables measured over several time points/periods (force and EMG during 345 
explosive voluntary contractions, evoked twitch and octet force) were analysed using a three-346 
way (group × session × time point) analysis of variance (ANOVA). Similarly, the force-347 
frequency relationship was assessed by a three-way (group × session × frequency) ANOVA. 348 
Other dependent variables (MVF, HRT, TPT, slope and intercept of force-EMG relationship, 349 
frequency at 50% of force response for the force-frequency relationship) were evaluated 350 
using two-way ANOVA (group × session).  A Greenhouse-Geisser correction was applied 351 
when the ANOVA assumption of sphericity was violated, and significant interaction effects 352 
were followed-up by independent sample t-tests on the individual percentage change values 353 
for each condition. The change in group mean values was used to calculate the percentage 354 
change values presented. Intra-individual variability was assessed using the mean intra-355 
individual coefficient of variation (CV) across the two measurement session for the PLA 356 
group [(mean ÷ standard deviation) × 100]. Statistical analyses were completed using SPSS 357 
version 21 (SPSS Inc, Chicago, USA) and statistical significance was accepted at P ≤ 0.05. 358 
Data are presented as mean ± one standard deviation (1SD).  359 
  360 
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RESULTS 361 
Electrically-evoked contractile properties 362 
Resting twitches 363 
There was no influence of supplementation on resting twitch force (P = 0.46 and 0.70, Figure 364 
1A), EMD (P = 0.63, Fig 2A) or TPT (P = 0.29; Fig 2B), although there was a group × 365 
session interaction for HRT (P = 0.018; Fig 2C).  Post hoc analysis showed that the change in 366 
HRT was greater for the BA group (-12 ± 10 %) compared to the PLA group (+2 ± 11%; P < 367 
0.01). Mean CV values for the PLA group were: force at 25, 50 ms and peak were 14%, 9% 368 
and 8%; EMD 7%; TPT 3%; HRT 7%. 369 
 370 
Potentiated twitches 371 
There was no influence of supplementation on potentiated twitch force (P = 0.44 and 0.52, 372 
Figure 1B), EMD (P = 0.48, Fig 2D) or TPT (P = 0.32; Fig 2E). However, there was a group 373 
× session interaction for HRT (P = 0.041; Fig 2F) and post hoc analysis showed that the 374 
change in HRT was greater for the BA group (-7 ± 11 %) compared to the PLA group (+1 ± 8 375 
%; P = 0.050). Mean CV values for the PLA group were: force at 25, 50 ms and peak were 376 
6%, 3% and 3%; EMD 6%; TPT 3%; HRT 4%. 377 
 378 
Octet contractions 379 
Supplementation did not influence resting octet force at any time point (Figure 1C). Mean 380 
CV values for the PLA group were: force at 25, 50 ms and peak were 10%, 3% and 4%. 381 
  382 
Force-frequency relationship 383 
The peak force at each frequency of stimulation (Fig 3) and the frequency at 50% of the force 384 
response (Table 1) were both unaffected by supplementation. Mean CV values for relative 385 
force (% maximum at 100 Hz) in PLA group were 6-8% at 1 - 10 Hz, 1-3% at 15 - 80 Hz, 386 
and 6% for the frequency at 50% of force response. 387 
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 388 
Maximum and explosive voluntary force production 389 
There was affect of supplementation on MVF (Fig 4). The mean CV for MVF in the PLA 390 
group was 3%. Similarly, there was no influence of supplementation on force measured at 25 391 
ms intervals during explosive voluntary contractions (Fig 4). The mean CV values for 392 
voluntary force production in the PLA group were: 13-17% at 25 – 50 ms, 4-7% from 75 – 393 
150 ms and 3% at MVF. 394 
 395 
Neuromuscular activation 396 
Agonist neuromuscular activation during maximum voluntary and explosive voluntary 397 
contractions 398 
Agonist EMG normalised to Mmax during MVCs and explosive contractions was not affected 399 
by supplementation (Fig 5), indicating that neuromuscular activation was consistent across 400 
measurement sessions. The mean CV values for agonist EMG in the PLA group were: 26%, 401 
23% and 9% in the 0-50, 50-100 and 100-150 ms time windows, and 13% at MVF. 402 
 403 
Force-EMG relationship 404 
The slope and y-intercept of the force-EMG relationship were unaffected by supplementation 405 
(Fig 5, Table 1). The mean CV value for slope of the force-EMG relationship in the PLA 406 
group was 15%. Although the CV was very high for the intercept of the relationship (80%) as 407 
a consequence of intercept values being close to zero, the mean difference between sessions 408 
was actually very low when expressed as a percentage of maximal EMG at MVF (4%).  409 
 410 
DISCUSSION 411 
The present study is the first to comprehensively examine the influence of BA 412 
supplementation on the electrically-evoked contractile properties of human skeletal muscle in 413 
vivo. BA supplementation had no effect on the force-frequency relationship, evaluated during 414 
submaximal muscle stimulation. Similarly, BA did not influence the EMD, explosive force 415 
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(at 25 and 50 ms), peak force or TPT of resting twitch, potentiated twitch or octet 416 
contractions elicited by supramaximal stimulation of the femoral nerve. In line with these 417 
findings, there were no changes in maximum or explosive voluntary force production 418 
following BA supplementation. The only significant effect of BA was a 12% and 7% 419 
reduction in HRT during resting and potentiated twitch contractions.  420 
 421 
Knee extensor intrinsic contractile properties 422 
The force-frequency relationship of the knee extensors was evaluated during submaximal 423 
muscle stimulation at a range of frequencies (1-100 Hz) in order to evaluate potential effects 424 
of BA supplementation on calcium handling and sensitivity, since an association between 425 
intracellular calcium levels and force production in response to different stimulation 426 
frequencies has previously been shown (5).  BA supplementation, however, had no effect on 427 
knee extensor force production at relatively low (1-15 Hz) or high (20-80 Hz) frequencies of 428 
muscle stimulation, corresponding to relatively low (19 – 53% force at 100 Hz) and high (63 429 
– 95% force at 100 Hz) levels of force. Previous in vitro research showed that increasing 430 
cytoplasmic carnosine levels from those normally present to levels approaching those 431 
attained after supplementation produced a marked enhancement in Ca
2+
 sensitivity (i.e., an 432 
increased force response to submaximal Ca
2+
 levels) of fibres from human m. vastus lateralis, 433 
as well as enhanced Ca
2+
 release in type I fibres (11). Thus the present data showing no effect 434 
of BA supplementation on the force-frequency relationship, the in vivo analogue of the force-435 
calcium concentration relationship (5; 27), responses might therefore be taken to imply that 436 
supplementation did not grossly influence Ca
2+
 sensitivity (10; 11) or Ca
2+
 release (11; 33).  437 
 438 
The present force-frequency data are supported by the findings that force and contraction 439 
time responses to supramaximal nerve stimulation at low- (resting and potentiated twitch) and 440 
high-frequencies (300 Hz, octet) were not affected by BA supplementation. Improved Ca
2+
 441 
sensitivity or release would be expected to be particularly beneficial in situations where 442 
calcium saturation is submaximal; during resting twitch contractions evoked by a single nerve 443 
impulse, for example. Combined evaluation of resting and potentiated twitch responses might 444 
have been expected to reveal any influence of BA supplementation on these processes, since 445 
the mechanisms for potentiation include the phosphorylation of myosin, which increases the 446 
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sensitivity of the contractile elements to Ca
2+
, as well as altered Ca
2+
 handling (39). However, 447 
neither peak force, TPT nor the rate of force development (force at 25 and 50 ms) of resting 448 
and potentiated twitches were affected by BA supplementation. Similarly, the resting and 449 
potentiated twitch EMD, which reflects the time for excitation-contraction coupling processes 450 
and for muscle shortening to remove slack from the muscle tendon unit (29; 31), was 451 
unaltered following BA supplementation. These data further imply that BA supplementation 452 
had little influence on Ca
2+
 sensitivity or release.  453 
 454 
The current data appear at odds with the human single fibre data mentioned above (11), and 455 
recent findings in mouse muscle where 10-31% increases in force were shown at frequencies 456 
between 25-125 Hz, but not at 1 Hz, following BA supplementation (13). Several factors 457 
could explain the present results and apparent contrast with the previous data. Firstly, there 458 
are obvious differences with the study of Dutka et al. (2012), including the manner by which 459 
they increased carnosine levels (acute exposure to a carnosine containing solution), the 460 
conditions of the muscle (skinned fibres devoid of connective tissue and not attached to bone) 461 
and the manner in which it was activated (exposure to Ca
2+
 buffered solutions), all of which 462 
bear little resemblance to the present in vivo study. Secondly, although enhanced Ca
2+
-463 
induced Ca
2+
 release was observed following exposure to carnosine in single fibre 464 
preparations (11), the authors concede that this may not occur in vivo, since this mechanism 465 
might have limited relevance to the control of Ca
2+
 release through ryanodine receptors by 466 
the dihydropyridine receptors (12; 25). Thirdly, species differences in carnosine metabolism 467 
and histidine-containing dipeptide content (4; 13) could explain the discrepancy between the 468 
data of Everaert et al. (2013) in mice and the data from the present study. The potential for 469 
inter-species differences is suggested by the fact that previous human data showed no fibre-470 
type differences in the carnosine-related changes in Ca
2+
 sensitivity (11), whilst there was 471 
some suggestion of fibre type differences in mice (i.e., differences in the response of “slow” 472 
soleus versus “fast” extensor digitorum longus muscles to BA supplementation) (13). It 473 
should be noted that we did not measure muscle carnosine content in the present study and so 474 
we cannot confirm the actual change due to BA supplementation or whether this directly 475 
relates to the individual responses in muscle contractile properties.  It is likely, given the 476 
previous data on the topic [e.g. (19)], that the increase in muscle carnosine would be around 477 
15 mmol.kg
-1
 dry muscle or +65% in these particpants, with this supplementation regimen.  478 
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 479 
Whilst the majority of the evoked contractile properties showed no change in response to BA 480 
supplementation, HRT decreased by 7-12% during resting and potentiated twitch 481 
contractions. Muscle relaxation is initiated by a reduction in sarcoplasmic reticulum Ca
2+
 482 
concentration. The rate of relaxation may be influenced by: (i) the rate of dissociation of Ca
2+
 483 
from troponin (26); (ii) the rate of translocation of Ca
2+
 to a site close to the sarcoplasmic 484 
reticulum (28); and (iii) the rate of re-uptake of Ca
2+ 
into the sarcoplasmic reticulum by 485 
ATPase driven Ca
2+
 pumps (30). At present, there do not appear to be any reports of 486 
carnosine influencing these aspects of excitation-contraction coupling. Interestingly, 487 
however, Everearts et al. (2013) reported an attenuation of the fatigue-related increases in 488 
relaxation times after BA supplementation in murine soleus muscle. Whilst their finding in 489 
this case could be a consequence of enhanced buffering capacity, during the repeated 490 
contractions, since BA supplementation had no influence on resting rate of relaxation, their 491 
report further highlight the functional implications of the present data. During fatigue, the 492 
rate of muscle relaxation slows as a consequence of a reduced rate of cross-bridge 493 
dissociation or impaired Ca
2+
 pumping into the sarcoplasmic reticulum (2).  The latter is 494 
energetically costly (30) and, as such, any improvements in Ca
2+
 handling with BA 495 
supplementation could reduce the total energy expenditure during high-intensity cyclic joint 496 
movements by reducing that energy cost, and also by improving the efficiency of joint 497 
movements by reducing co-contraction.  Future research should attempt to confirm the 498 
present findings and extend them by investigating the changes in evoked contractile 499 
properties during fatigue in order to better understand the influence of BA supplementation 500 
on muscle contractility and implications for metabolic and movement efficiency during 501 
exercise. 502 
   503 
Voluntary force production and motor control 504 
BA supplementation had no effect on MVF, a finding consistent with the lack of changes in 505 
electrically-evoked twitch or tetanic (octet) peak force in the present study. Maximum 506 
isometric force is not affected by either increased Ca
2+
 sensitivity or increased myoplasmic 507 
Ca
2+
 concentration (27), and previous studies reported minimal effects of carnosine on 508 
maximum calcium activated force (0-3% increase) (11) and of BA supplementation on 509 
maximal twitch and tetanic force (13). Improved Ca
2+
 sensitivity or release would be 510 
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expected to be beneficial for force production in situations where calcium saturation is 511 
submaximal [e.g., during the rising phase of voluntary force production where neuromuscular 512 
activation is submaximal, (14)] and during sustained submaximal contractions. Thus, one 513 
might have expected improvements in explosive voluntary force and/or alterations in the 514 
force-EMG relationship, indicative of the change in neuromuscular activation required to 515 
produce a given change in force, if BA supplementation had influenced these Ca
2+
 related 516 
functions. However, in accordance with the lack of changes in the force-frequency 517 
relationship, as well as the force responses during twitch and octet contractions, BA 518 
supplementation did not influence voluntary explosive force or the force-EMG relationship. 519 
The similar neural drive during both the maximum voluntary contractions and explosive 520 
voluntary contractions confirm that the force results were not confounded by changes in 521 
neuromuscular activation over time.  522 
 523 
Conclusions 524 
The results of the present study showed that BA supplementation had no effect on the force-525 
frequency relationship, implying a lack of any effect on muscle Ca
2+
 sensitivity or release. In 526 
support of these data, there was no effect of BA supplementation on force responses to 527 
resting and potentiated twitches and octet contractions. As such, the study findings do not 528 
support the idea that exercise performance and capacity improvements after BA 529 
supplementation are due to enhanced Ca
2+
 sensitivity or release.  We do, however, show a 530 
reduction in HRT with BA supplementation, which might possibly be explained by enhanced 531 
reuptake of Ca
2+
 into the sarcoplasmic reticulum.  This has potentially important implications 532 
for the efficiency of muscle contraction following BA that should be explored in future 533 
studies, since this could conceivably contribute to the ergogenic potential of BA 534 
supplementation during high-intensity exercise involving rapid muscle contractions.  535 
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Figure legends 660 
 661 
Figure 1. Electrically-evoked force of BA and PLA groups pre- and post-supplementation: 662 
(A), resting twitch force; (B), potentiated twitch force; (C), octet force. Data are mean ± 1SD. 663 
26 
 
Figure 2. Contraction times during twitch contractions evoked via femoral nerve stimulation 664 
for BA and PLA groups pre- and post-supplementation. Resting twitch: EMD (A); TPT (B); 665 
and HRT (C). Potentiated twitch: EMD (D); TPT (E); and HRT (F).  Data are mean ± 1SD. 666 
**P ≤ 0.01 and *P ≤ 0.05 for post-hoc independent t-test on % change values in BA and PLA 667 
groups. 668 
Figure 3. Force-frequency relationship assessed during submaximal percutaneous stimulation 669 
for BA and PLA groups pre- and post-supplementation. Data are mean ± 1SD. 670 
Figure 4. Explosive and maximum voluntary force of BA and PLA groups pre- and post-671 
supplementation (A).  Agonist EMG normalised to Mmax during explosive contractions (0-50, 672 
50-100 and 100-150 ms from onset) and at MVF for the BA and PLA groups pre- and post-673 
supplementation (B). Data are mean ± 1SD. 674 
Figure 5. Force-EMG relationship measured during submaximal voluntary contractions (15 – 675 
90% MVF) for BA and PLA groups pre- and post-supplementation. Data are mean ± 1SD. 676 
  677 
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Tables 678 
 679 
Table 1. Characteristics of the force-frequency and force-EMG relationships of BA and 
PLA groups pre- and post-supplementation. Data are mean ± 1SD.  
 Pre Post 
 BA PLA BA PLA 
Force-frequency relationship     
Frequency at 50% of force 
response (Hz) 
17.3 ± 2.4 18.8 ± 1.5 16.8 ± 1.7 18.0 ± 1.9 
Force-EMG relationship     
Intercept (RMS:Mmax) -0.49 ± 0.74 -0.70 ± 0.47 -0.53 ± 0.91 -0.56 ± 0.43 
Slope (RMS:Mmax·N
-1) 0.0175 ± 
0.0054 
0.0180 ± 
0.0035 
0.0174 ± 
0.0037 
0.0170 ± 
0.0037 
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 BA PLA BA PLA 
Force-frequency 
relationship 
    
Frequency at 50% of force 
response (Hz) 
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Force-EMG relationship     
Intercept (RMS:Mmax) -0.49 ± 0.74 -0.70 ± 0.47 -0.53 ± 0.91 -0.56 ± 0.43 
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